Digestive health

The Blood Test for Colon Cancer: What It Can and Can't Do

Save

A blood draw is an easier ask than a stool sample or a bowel prep, and that convenience is real. What matters just as much is how a new test's numbers compare to the screening options with decades of evidence behind them — colonoscopy, the FIT test, and stool DNA testing — and what actually happens after a result comes back positive, whichever test produced it.

Last updated: July 2026History

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Is There a Blood Test for Colon Cancer?

Yes — blood-based screening tests for colorectal cancer are now part of the screening landscape, joining stool-based tests and colonoscopy rather than replacing them. Professional guidelines rank colonoscopy every ten years and annual FIT as first-tier screening options, with stool DNA testing and CT colonography as second-tier alternatives 1; a blood-based option is newer still than that tiering, with less of a long-term track record behind it than either tier.

That doesn't make a blood test a bad choice. For someone who won't complete a stool-based test or colonoscopy at all, a blood draw they'll actually finish beats a gold-standard test they keep avoiding. It does mean the fair comparison is against tests with a much longer evidence base, and that's where the real tradeoffs show up.

Where It Fits Among Established Non-Invasive Options

The fecal immunochemical test — the fit test, done with a single stool sample analyzed once a year — has moderate sensitivity and high specificity for colorectal cancer, meaning it catches a majority of cancers while producing relatively few false positives 2. The multitarget stool DNA test, marketed as Cologuard, takes a different approach, combining DNA markers with blood detection in a stool sample.

Cologuard's next-generation version was evaluated in a large average-risk screening population and is the current benchmark for that test's performance, superseding the original 2014 data 3. Both FIT and Cologuard are done at home and mailed to a lab — the meaningful differences between them are frequency (annual for FIT, generally every three years for Cologuard) and the sensitivity-specificity tradeoff each one makes.

Why Colonoscopy Still Anchors the System

Colon polyps are growths on the lining of the colon or rectum that are usually benign, but some can become cancerous over time, which is the entire rationale for screening in the first place: finding and removing a polyp before it becomes cancer 4. Colonoscopy is the only screening method that finds and removes a polyp in the same procedure, which is why every non-invasive test — stool-based or blood-based — ultimately routes back to it.

A positive result on a stool-based screening test is followed by a diagnostic colonoscopy, and under the ACA that follow-up colonoscopy is covered as screening rather than billed as a separate diagnostic procedure, with no patient cost-sharing 5. The same is a reasonable expectation for a positive blood-based result, though the specific coverage treatment of a blood test's follow-up colonoscopy is worth confirming with an insurer directly rather than assumed to match the stool-test rule exactly.

Who Screening Guidelines Say Should Start, and When

Average-risk adults are now recommended to start colorectal cancer screening at 45 rather than 50, a change the U.S. Preventive Services Task Force made in 2021 — grade B for ages 45 to 49, grade A for 50 to 75 6. That age-45 screening change reflects colorectal cancer showing up more often in younger adults than it used to, and it applies regardless of which screening method someone eventually chooses.

Which test to choose is a separate question from when to start, and guidelines generally leave that choice to the patient and clinician together rather than mandating one method. The right test is the one a person will actually complete on schedule — colonoscopy every ten years, annual FIT, Cologuard on its own interval, or a newer blood-based option.

How to Read Any New Screening Test's Numbers

Two numbers describe how well any screening test performs: sensitivity, the share of actual cancers it correctly flags, and specificity, the share of cancer-free people it correctly clears. A test can be highly sensitive and still generate false positives if its specificity is lower, and each false positive leads to a colonoscopy that finds nothing — a real cost in time, bowel prep, and anxiety, even though it isn't a health risk.

The original Cologuard study reported higher single-test sensitivity than FIT but lower specificity 23, a genuine tradeoff rather than a simple upgrade — more cancers caught, more unnecessary follow-up colonoscopies too. Any newer test, blood-based included, is worth evaluating on that same pair of numbers from a peer-reviewed, average-risk population study, rather than on a marketing claim about convenience alone. Convenience that leads to more people actually getting screened has real value, but it doesn't substitute for knowing what a test actually catches and what it misses.

The Billing Distinction That Determines What You Pay

Whether a colon cancer screening test is billed as screening or diagnostic is often the single biggest factor in what it costs, regardless of which test comes back positive. A colonoscopy performed as follow-up to a positive stool-based or blood-based test is generally covered as screening with no cost-sharing under the ACA, rather than treated as a new diagnostic procedure that resets a deductible 5.

That distinction can get murky in practice. A colonoscopy that starts as a screening exam and turns into a polypectomy once a polyp is found is one of the more common sources of an unexpected bill, since some plans have historically billed that combination differently depending on state rules. Asking a scheduler directly how the visit will be coded, and confirming it in writing before the procedure, is more reliable than assuming any screening test's follow-up will automatically be free.

What a Result Doesn't Change

A negative result on any screening test, blood-based included, applies to someone without symptoms being screened on schedule — it isn't a reason to dismiss new symptoms that show up afterward. The symptoms that earn a colonoscopy outside of routine screening — rectal bleeding, a persistent change in bowel habits, unintentional weight loss — are a different, higher-urgency pathway than any screening test, and a recent negative screen doesn't rule them out.

Knowing colon cancer warning signs matters independent of any screening test's schedule, since symptoms can appear between scheduled screenings regardless of a recent negative result. The same logic applies to two related questions this overlaps with: is it ibs or colon cancer is worth reading directly if bowel-habit changes are the concern, and blood in stool that shows up between screenings is its own evaluation, not something a recent screening result should wave away.

Common questions

A blood test analyzes a blood draw instead of a stool sample, which is a real convenience for people who won't complete a stool-based test. It's also newer, with less long-term evidence behind it than FIT or Cologuard, both of which have been studied in large screening populations for years.

No — a positive result on any non-invasive screening test, blood-based or stool-based, means a diagnostic colonoscopy is the next step, not a diagnosis on its own. Colonoscopy is what actually finds and, if needed, removes a polyp or confirms a cancer; the screening test is a filter for who needs that closer look.

No screening test, including colonoscopy itself, is perfect, but colonoscopy remains the reference standard because it can find and remove a polyp in the same procedure. Any non-invasive test, blood-based included, is a filter that determines who needs a colonoscopy — not a replacement for one when a result is positive.

Average-risk adults are recommended to start at 45, per the 2021 USPSTF update — a change from the previous starting age of 50. People with a family history or other risk factors are often advised to start earlier, which is a conversation worth having directly with a clinician.

Coverage rules for stool-based screening tests and their follow-up colonoscopy are well established under the ACA's no-cost-sharing requirement, but the specific coverage terms for newer blood-based tests vary by plan and are worth confirming directly with an insurer before scheduling.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When symptoms matter more than a screening schedule

  • —Rectal bleeding or blood in the stool, at any age
  • —A persistent change in bowel habits lasting more than a few weeks
  • —Unintentional weight loss
  • —Iron deficiency anemia without an obvious cause

Heavy rectal bleeding, dizziness, or fainting warrants emergency care — call 911 or go to the nearest ER. Bleeding that's new but mild, or any of the other symptoms above, warrants a prompt call to a clinician rather than waiting for a scheduled screening.

This article explains general patterns and clinical guidance; it isn't a substitute for an evaluation from a clinician.

Did this answer your question?

References

  1. 1.Rex DK, Boland CR, Dominitz JA, et al. (U.S. Multi-Society Task Force on Colorectal Cancer) (2017). Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy. doi:10.1016/j.gie.2017.04.003 ✓Supports the tiered ranking of colonoscopy and FIT as first-tier screening, with stool DNA testing and CT colonography as second-tier options.
  2. 2.Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014). Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Annals of Internal Medicine. doi:10.7326/M13-1484 ✓Supports the FIT test's pooled sensitivity of about 0.79 and specificity of about 0.94 for colorectal cancer.
  3. 3.Imperiale TF, Porter K, Zella J, et al. (BLUE-C Study Investigators) (2024). Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening. New England Journal of Medicine. doi:10.1056/NEJMoa2310336 ✓Supports the next-generation Cologuard test's sensitivity and specificity figures from the BLUE-C average-risk screening trial, as the current benchmark superseding the 2014 first-generation data.
  4. 4.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2017). Definition & Facts for Colon Polyps. NIDDK, National Institutes of Health. link ✓Supports the definition of colon polyps as usually-benign growths that can become cancerous over time, the rationale for screening and removal.
  5. 5.American Cancer Society (2024). Insurance Coverage for Colorectal Cancer Screening. American Cancer Society (cancer.org). link ✓Supports that a follow-up colonoscopy after a positive stool test is covered as screening with no patient cost-sharing under the ACA.
  6. 6.U.S. Preventive Services Task Force (USPSTF) (2021). Colorectal Cancer: Screening (Final Recommendation). U.S. Preventive Services Task Force. link ✓Supports the authoritative statement that recommended average-risk colorectal cancer screening begins at age 45, grade B for 45-49 and grade A for 50-75.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library